Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of diflunisal on familial transthyretin amyloidosis
2014-001957-17Phase 3Completed
- Sponsor
- Umeå University Hospital
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of diflunisal in hereditary transthyretin amyloidosis (hATTR) and familial amyloid cardiomyopathy (FAC), sponsored by Umeå University Hospital. Primary endpoint: Neurological, nutritional and cardiac disease progression. Started Jul 2015; status: completed.
02
Drugs
diflunisal
03
Conditions
hereditary transthyretin amyloidosis (hATTR)familial amyloid cardiomyopathy (FAC)
Beyond the preview
Go deeper on 2014-001957-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001957-17.